Filana Therapeutics (FLNA) Operating Expenses (2010 - 2026)

Filana Therapeutics has reported Operating Expenses for 17 years, with the latest figure at $9.4 million in Q2 2026.

• On a quarterly basis, Operating Expenses fell 79.31% year-over-year to $9.4 million in Q2 2026; TTM through Jun 2026 was $46.0 million, a 64.66% decrease from a year earlier, with the FY2025 full-year figure at $95.4 million, down 32.56% from the prior year.
• Operating Expenses was $9.4 million for Q2 2026 at Filana Therapeutics, down from $11.2 million in the prior quarter.
• The five-year high for Operating Expenses was $61.4 million in Q2 2024, with the low at $9.4 million in Q2 2026.
• Average Operating Expenses over 5 years is $24.6 million, with a median of $22.1 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: Operating Expenses soared 404.42% in 2022, then tumbled 79.31% in 2026.
• Over 5 years, Operating Expenses stood at $20.9 million in 2022, then advanced by 8.85% to $22.8 million in 2023, then rose by 29.39% to $29.5 million in 2024, then sank by 54.04% to $13.6 million in 2025, then slumped by 30.69% to $9.4 million in 2026.
• The last three Operating Expenses figures came in at $9.4 million (Q2 2026), $11.2 million (Q1 2026), and $13.6 million (Q4 2025), per Business Quant data.